WHO ICTRP trial
The study of feasibility and usefulness of olanzapine for the patients who…
JPRN-UMIN000032591 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000032591 |
|---|---|
| Public title | The study of feasibility and usefulness of olanzapine for the patients who received oxaliplatin chemotherapy. |
| Scientific title | The study of feasibility and usefulness of olanzapine for the patients who received oxaliplatin chemotherapy. - The study of feasibility and usefulness of olanzapine for the patients who received oxaliplatin chemotherapy. |
| Primary sponsor | Osaka International Cancer Institute |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | colorectal cancer |
| Interventions | Olanzapine; 5mg PO on days 1 to 4 Aprepitant; 125 mg PO on day 1, 80 mg PO on days 2 to 3 5HT3-receptor antagonist; IV administration on day 1 Dexamethasone; 6.6 mg IV on day 1, 4 mg PO on days 2 to 3 |
| Registration date | May 15, 2018 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: